Table 1.

Progression rates in terms of TFC decline in randomized and observational studies. Shown are mean values of annual TFC change estimated for each study listed; negative values indicate worsening on this scale. For Pride-HD, exact baseline data were not available; however, the study population was similar to, e.g., the HART study population, i.e. ambulatory patients, a large proportion in TFC stage I or II. The delay of TFC decline observed in pridopidine treated subjects was particularly evident in the early-stage population. CoQ: Coenzyme Q. HSG: Huntington study Group

Study	Baseline TFC	Treatment	Annual TFC progression	Follow-up time
HSG [121]	7.5	Observational	–0.72	18 (median)
HSG [121]	Stage 2 (tfc 7–10)	Observational	–0.84	18 mo
REGISTRY [122]	8 (M), 7.4 (F)	Observational	–0.74(M), 0.94 (F)	21 mo
CARE-HD [123]	10.3	Placebo	–1.096	30 mo
CARE-HD [123]	10.1	CoQ	–0.96	30 mo
CARE-HD [123]	10.0	Remacemide	–1.08	30 mo
2CARE [124]	11.0	Placebo	–0.952	60 mo
2CARE [124]	10.8	CoQ	–0.906	60 mo
CREST-E [125]	10.2	Placebo	–0.7	18–48 mo
CREST-E [125]	10.2	Creatine	–0.82	18–48 mo
Tetra-HD continuation [126]	7.6	Tetrabenazine	–1.3	18 mo
Open-HART [67]	9.1 (cohort completing 36 mo)	Pridopidine	–0.57	36 mo
Open-HART [67]	8.4 (cohort completing 12 mo)	Pridopidine	–0.6	12 mo
Pride-HD [66]	–	Pridopidine	–0.04	12 mo
Pride-HD [66]	–	Placebo	–0.83	12 mo